BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19570422)

  • 1. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
    Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and pathological features of borderline ovarian tumors].
    Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?
    Benito V; Lubrano A; Arencibia O; Medina N; Álvarez Eva E; Andújar M; Falcón Juan M; Falcón O
    Eur J Obstet Gynecol Reprod Biol; 2010 Dec; 153(2):188-92. PubMed ID: 20728981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
    Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
    Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Borderline ovarian tumors].
    Ivanov S
    Akush Ginekol (Sofiia); 2002; 42(1):23-5. PubMed ID: 11935694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary.
    Kane A; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
    Fertil Steril; 2010 Dec; 94(7):2891-4. PubMed ID: 20537629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
    Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in studies of ovarian serous and mucinous borderline ovarien tumors].
    Shao HL; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2006 Mar; 35(3):173-5. PubMed ID: 16630508
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
    Tang L; Zheng M; Xiong Y; Ding H; Liu FY
    Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths.
    Alshenawy HA
    Ann Diagn Pathol; 2010 Dec; 14(6):387-95. PubMed ID: 21074685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of prognostic factors of epithelial ovarian carcinoma].
    Shao SL; Liu XS
    Zhonghua Fu Chan Ke Za Zhi; 2010 Feb; 45(2):132-6. PubMed ID: 20420785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.